Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue 2, 2009, Pages 124-131

  Canovas M ^a,e   Delgadillo, J ^b   Torres, F ^b   Riba, N ^c   Cebrecos, J ^d   Pelagio, P ^d   Cabre F ^a  

^a Laboratorios Lesvi SL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d Laboratorio de Analisis Dr Echevarne   (Spain)

^e Laboratorios Lesvi   (Spain)

Author keywords

Bioequivalence; Healthy subjects; Pharmacokinetics; Risperidone; Tablet

Indexed keywords

CLOZAPINE; PALIPERIDONE; RISPERIDONE; 9 HYDROXY RISPERIDONE; 9-HYDROXY-RISPERIDONE; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PYRIMIDINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; FEMALE; GEOMETRY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONPARAMETRIC TEST; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; PHARMACOKINETICS; PRACTICE GUIDELINE; TABLET; TIME; UNITED STATES;

ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; EUROPEAN UNION; FEMALE; GUIDELINES AS TOPIC; HUMANS; ISOXAZOLES; MALE; PYRIMIDINES; RISPERIDONE; TABLETS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 62749159078     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP47124     Document Type: Article

References (18)

1. Borison RL, Diamond B, Pathiraja A, Meibach RC. Pharmacokinetics of risperidone in chronic schizophrenic patients. Psychopharmacol Bull. 1994; 30: 193-197.
2. Cho HY, Lee YB. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res. 2006; 29: 525-533.
3. CPMP Committee for Proprietary Medicinal Products. Note for guidance on the investigation of bioavailability and bioequivalence. The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit. 2001; (CPMP/EWP/QWP/1401/98).
4. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 1-8.
5. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 (Suppl. 11): 12-25.
6. Fang J, Bourin M, Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol. 1999; 359: 147-151.
7. Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994; 48: 253-273.
8. Gutierrez R, Lee PI, Huang ML, Woesterborghs R. Risperidone: effects of formulations on oral bioavailability. Pharmacotherapy. 1997; 17: 599-605.
9. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-78.
10. Health Canada. Guidance for Industry. Drugs Directorate Guidelines. Conduct and Analysis of Bioavailability and Bioequivalence Studies. Part A: Oral dosage formulations used for systemic effects. Minister of Public Works and Government Services Canada, 1992; (H42-2/ 56-1992E).
11. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994; 55 (Suppl): 13-17.
12. Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. Pharmacokinetics of the novel antipsychotic agent risperidone and prolactin response in healthy subjects. Clin Pharmacol Ther. 1993; 54: 257-268.
13. ICH E6. Good Clinical Practise: Consolidated Guidance; 1996.
14. Möller HJ. Risperidone: a review. Expert Opin Pharmacother. 2005; 6: 803-818.
15. Risperdal® SmPC. Electronic Medicines Compendium. www.medicines.org.uk; 2004.
16. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-680.
17. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000; 17: 1551-1557.
18. Wijnand HP. Updates of bioequivalence programs (including statistical power approximated by Student's t). Comput Methods Programs Biomed. 1994; 42: 275-281.